METYRAPONE ESTEVE

Posology Diagnostic Applications (i) Short single-dose test – diagnosis of ACTH insufficiency This can be performed on an ambulatory basis. In this test, plasma 11-desoxycortisol and/or ACTH levels are determined after a single dose of Metyrapone Esteve.

The patient is given 30 mg/kg (maximum 3 g Metyrapone Esteve) at midnight with yoghurt or milk to minimise nausea and vomiting. Patients with suspected adrenocortical insufficiency should be hospitalised overnight as a precautionary measure.

Paediatric population The same dose as in adults is recommended in children. The blood sample for the assay is taken early in the morning (7:30 – 8:00 hours). The plasma should be frozen as soon as possible. The patient is then given a prophylactic dose of 50 mg cortisone acetate.

Evaluation:

Normal values will depend on the method used to determine ACTH and 11- desoxycortisol levels. 2 micromol/L (70 microg/L). Healthy individuals have an ACTH response of 42 to 690 pg/mL (9 to 210 pmol/L). In general, patients with partial secondary adrenal insufficiency have ACTH responses from 10 to 200 pg/mL (2 to 44 pmol/L), while patients with primary adrenal insufficiency have higher responses.

Because of this overlap, the ACTH response alone cannot be used to distinguish between healthy individuals and those with adrenal insufficiency. (ii) Multiple-dose test – diagnosis of ACTH insufficiency and differential diagnosis of adrenocortical hyperfunction in Cushing’s syndrome.

The patient must be hospitalised. In this test, urinary steroid levels are measured. The first day, baseline values are determined for the 24 hours preceding the test. 5 g. The effect is evaluated in two consecutive 24-hour urinary samples.

Maximum urine steroid excretion may occur on the fourth day. If urinary steroid excretion increases in response to Metyrapone Esteve, this suggests the high levels of circulatory cortisol are due to adrenocortical hyperplasia following excessive ACTH production rather than a cortisol- producing adrenal tumour.

Paediatric population The paediatric dosage recommendation is based on limited data. In children the dosage should be 15 mg/kg body weight, with a minimum dose of 250 mg every 4 hours for 6 doses. It is recommended that patients take the capsules with milk or after meals to minimise nausea and vomiting.

Evaluation:

ACTH deficiency: If the anterior pituitary is functioning normally, Metyrapone Esteve brings about a marked increase in 17-hydroxycorticosteroids (17–OHCS) or 17 ketogenic steroids (17–KGS) in the urine (to at least twice baseline levels).

Lack of response indicates secondary adrenocortical insufficiency.

Cushing’s syndrome:

An excessive increase in 17–OHCS or 17–KGS in the urine after administration of Metyrapone Esteve indicates over-production of ACTH which has led to adrenocortical hyperplasia (Cushing’s syndrome). Such an increase can be taken as an indication that there is no adrenocortical tumour producing cortisol autonomously.

Therapeutic use Adults For the management of Cushing’s syndrome, the initial dose of metyrapone may vary from 250 to 1500 mg/day depending on the severity of hypercortisolism and the cause of Cushing’s syndrome. Metyrapone may be initiated at doses of 750 mg/day for patients with moderate Cushing’s syndrome.

For patients with severe Cushing’s syndrome, initiation doses may be higher, up to 1500 mg/day. Lower starting doses may be used in cases of mild Cushing’s disease or adrenal adenoma or hyperplasia. The usual maintenance dose varies between 500 and 6000 mg/day.

The dose should be given in three or four divided doses. The daily dose should be adjusted after a few days with the aim of lowering the mean plasma/serum cortisol levels and/or the 24-hour urinary free-cortisol levels to a normal target value or until the maximal tolerated dose of metyrapone is reached.

Mean serum/plasma cortisol levels may be calculated from the average of 5 to 6 plasma/serum samples obtained throughout a day or from cortisol levels obtained just before the morning dose. Once weekly monitoring of plasma/serum cortisol levels and/or a 24-hour free urinary cortisol levels is necessary to allow further dose adjustments if needed.

The dose-adjustment period is usually 1 to 4 weeks. When cortisol levels are close to the optimal levels, longer periods (generally once a month or every 2 months) are sufficient for the monitoring. A physiological corticosteroid replacement therapy may be added to a complete cortisol blockade by metyrapone (block-and-replace regimen).

This should be started when the serum or urine cortisol is in the normal range and the metyrapone doses are increased to achieve complete suppression of cortisol secretion. In case of rapid dose-escalation or for patients with cyclic Cushing’s syndrome, a physiological corticosteroid replacement therapy may be added.

For the treatment of resistant oedema:

The usual daily dose of 3g (12 capsules) should be given in divided doses in conjunction with a glucocorticoid.

Special populations Paediatric population:

The paediatric dosage recommendation is based on limited data. Case reports showed that there is no specific dosage recommendation for paediatric use in the treatment of Cushing’s syndrome. The dose should be adjusted on an individual basis as a function of cortisol levels and tolerability.

Elderly population:

Dosage as for adults. There is limited data available on the use of metyrapone in elderly (≥ 65 years old). Clinical evidence would indicate that no special dosage regimen is necessary. Method of administration The capsules should be taken with milk or after a meal, to minimise nausea and vomiting, which can lead to impaired absorption.

Safety data are derived from spontaneous reports, published literature and PROMPT study (prospective single-arm, open-label study, 50 patients included in safety data set). Adverse drug reactions (Table 1) are listed according to system organ classes and preferred terms in MedDRA using the following convention: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000) very rare (<1/10,000), not known (cannot be estimated from the available data).

Table 1. Adverse drug reactions Frequency SOC / Preferred TermSystem Organ Class Very common (≥1/10) Common (≥1/100, <1/10) Not known Blood and lymphatic system Leukopenia, anaemia, thrombocytopenia disorders Endocrine disorders Adrenal insufficiency* Metabolism and nutrition disorders Decreased appetite* Hypokalaemia Nervous system disorders Headache* Dizziness* Sedation Vascular disorders Hypertension Hypotension* Gastrointestinal disorders Nausea* Abdominal pain* Diarrhoea Vomiting* Hepatobiliary disorders Hepatic enzymes increased Skin and subcutaneous tissue disorders Hypersensitivity reactions including rash, pruritus and urticaria Hirsutism** Acne Alopecia Musculoskeletal and connective tissue disorders Arthralgia Myalgia Infections and Infestations Pneumocystis jirovecii pneumonia General disorders and administration site conditions Asthenic conditions Peripheral oedema * Mainly during titration period / dose increase **Reported cases occurred in the PROMPT study following treatment of 12 to 36 weeks duration Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Diagnostic applications The metyrapone diagnostic test should be restricted to referral hospital centers. Patients with reduced adrenal secretory capacity and serious hypopituitarism The ability of the adrenal cortex to respond to exogenous ACTH should be demonstrated before Metyrapone Esteve is employed as a test, as Metyrapone Esteve may induce acute adrenal insufficiency in patients with reduced adrenal secretory capacity, as well as in patients with global pituitary insufficiency.

The test should be performed in hospital with close monitoring in case of suspected adrenocortical insufficiency. Patients with hypothyroidism or taking drugs affecting the hypothalamo-pituitary adrenal axis In cases of thyroid hypofunction, urinary steroid levels may rise very slowly, or not at all, in response to Metyrapone Esteve.

5). If adrenocortical or anterior pituitary function is more severely compromised than indicated by the results of the test, Metyrapone Esteve may trigger transient adrenocortical insufficiency. This can be rapidly corrected by giving appropriate doses of corticosteroids.

Reduced liver function Patients with liver cirrhosis often show a delayed response to Metyrapone Esteve, due to liver damage delaying the metabolism of cortisol. Therapeutic use Hypocortisolism The product should only be used under the supervision of specialists having available the appropriate facilities for monitoring of clinical and biochemical responses.

Treatment with Metyrapone Esteve leads to rapid decrease in circulating levels of cortisol and potentially to hypocortisolism/hypoadrenalism. g. weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyperkalaemia, hyponatraemia, hypoglycaemia).

In the event of documented hypocortisolism, temporary exogenous steroid (glucocorticoid) replacement therapy and/or dose reduction or interruption of Metyrapone Esteve therapy may be necessary. Assay methods A reliable assay without cross-reactivity with steroids precursors, such as a specific immuno-assay or a liquid chromatography-mass spectrometry (LC-MS/MS) method, to measure plasma/serum and urine cortisol levels is recommended to allow accurate metyrapone dose adjustment.

Patients with severe Cushing’s syndrome Severe Cushing’s syndrome is known to increase the risk of opportunistic infections such as Pneumocystis jirovecii pneumonia due to immunosuppression and anti- inflammatory effect of hypercortisolism.

Generally, infection must be anticipated in such patients and careful management is warranted Initiation of an appropriate prophylactic treatment may be considered. Hypertension Long-term treatment with Metyrapone Esteve can cause hypertension as the result of excessive secretion of desoxycorticosterone.

Hypokalaemia Hypokalaemia can occur in patients with Cushing’s syndrome and during Metyrapone Esteve treatment. Potassium levels should be checked before therapy start and monitored periodically during therapy. Any hypokalaemia prior to Metyrapone Esteve administration and/or during therapy should be corrected.

QTc prolongation In a clinical study performed in patients with Cushing’s syndrome treated with metyrapone (PROMPT, prospective single-arm, open-label study, 50 patients included in safety data set), three patients had an asymptomatic increase in QTcF interval above 60 ms.

No patient had an increase of QTcF interval above 480 ms. Metyrapone should be used with caution in patients with relevant pre-existing cardiac diseases and/or electrolyte disturbances. If signs of cardiac arrhythmia occur during treatment with Metyrapone Esteve, monitoring of ECG and electrolytes are recommended.

Excipients The presence of the excipients sodium ethyl parahydroxybenzoate (E215) and sodium propyl parahydroxybenzoate (E217) may cause allergic reactions (possibly delayed). This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium free’.

Primary adrenocorticol insufficiency. 1.